US Patent 10,603,280: Claim Scope, Patent Strength, Exclusivity and Competitive Landscape
US Patent 10,603,280 protects a moisture-control pharmaceutical dosage form rather than a specific active ingredient. Its independent claims require an HPMC capsule containing a defined mixture of a moisture-sensitive active ingredient, trimagnesium dicitrate, and microcrystalline cellulose. The patent’s commercial reach depends on whether a marketed product uses all of those elements, including the specified moisture thresholds.
The claims do not cover trimagnesium dicitrate as an active ingredient. They require another moisture-sensitive active ingredient in a concentration of 20% to 40% by weight.
What does US Patent 10,603,280 protect?
The core invention is a non-effervescent solid medicinal form in an HPMC capsule. The capsule filling must contain:
| Required element |
Claim 1 requirement |
| Dosage form |
Non-effervescent solid medicinal form |
| Capsule shell |
Hydroxypropylmethylcellulose, or HPMC |
| Moisture-sensitive active ingredient |
20% to 40% by weight |
| Trimagnesium dicitrate |
20% to 50% by weight |
| Microcrystalline cellulose |
5% to 30% by weight |
| Moisture performance |
Relative equilibrium moisture of no more than 15% at 25°C |
| Active-ingredient exclusion |
Active ingredient cannot be trimagnesium dicitrate |
The patent therefore covers a formulation architecture in which trimagnesium dicitrate functions as an internal drying agent. It is not limited to one named pharmaceutical compound.
The practical scope is narrower than the broad phrase “moisture-sensitive active ingredient” suggests. An accused product must satisfy the composition ranges, dosage-form requirements and moisture limitation. A product using a gelatin capsule, a tablet, a liquid-filled capsule or a different drying agent would not literally meet claim 1.
How do the independent claims differ?
Claims 1 and 9 are the principal independent formulation claims.
| Claim |
Key distinction |
| Claim 1 |
Requires relative equilibrium moisture of no more than 15% for the medicinal form |
| Claim 9 |
Requires equilibrium moisture of less than 10% for the capsule filling |
Claim 9 is not merely a narrower version of claim 1 in measurement terms. It changes the measured subject from the “medicinal form” to the “capsule filling” and uses the stricter threshold of less than 10%.
That distinction creates possible validity and infringement issues involving:
- whether moisture is measured on the complete capsule or only its contents;
- whether “equilibrium moisture” and “relative equilibrium moisture” have the same technical meaning;
- test temperature and equilibration conditions;
- sample conditioning and analytical method;
- whether the claimed measurement is a limitation or only a performance result.
The intrinsic claim language should control those issues, supplemented by the specification and prosecution history. A generic product that satisfies the composition ranges but does not demonstrate the claimed moisture result may avoid literal infringement if the moisture limitation is enforced as a structural claim element.
What dependent claims add to the patent?
Claims 2 through 8 and 10 through 11 add formulation and packaging limitations.
| Claim |
Added limitation |
| 2 |
Microcrystalline cellulose is 10% to 20% by weight |
| 3 |
Relative equilibrium moisture is no more than 10% |
| 4 |
Stearic acid is 0.3% to 2% by weight |
| 5 |
Stearic acid is 1% to 2% by weight |
| 6 |
Silica is 0.2% to 2% by weight |
| 7 |
External drying agent and tight, substantially water-impermeable packaging |
| 8 |
Active ingredient and trimagnesium dicitrate are dry granulated together |
| 10 |
Relative equilibrium moisture is 1% to 6% |
| 11 |
Capsule-filling equilibrium moisture is less than 6% |
Claims 4 and 5 overlap. Claim 5 is a narrower concentration range within claim 4. Claim 10 is also narrower than claim 3 from a moisture-performance perspective, although the measurement wording differs.
Claim 7 is commercially important because it adds the external package. A product may infringe claim 1 without infringing claim 7 if the package lacks an external drying agent or does not meet the water-impermeability requirement.
Claim 8 targets the manufacturing process. It requires dry granulation of the active ingredient and trimagnesium dicitrate together. A product made by wet granulation, direct blending or separate granulation may fall outside claim 8 while remaining within the composition claims.
What formulations are protected by US Patent 10,603,280?
The broadest protected formulation must fall within the following numerical intersection:
- active ingredient: 20% to 40%;
- trimagnesium dicitrate: 20% to 50%;
- microcrystalline cellulose: 5% to 30%;
- HPMC capsule;
- non-effervescent solid form;
- no more than 15% relative equilibrium moisture at 25°C.
The ranges are open to multiple combinations because the claims do not require the three listed ingredients to total 100%. Other excipients may be present, subject to the overall composition and claim interpretation.
Potentially covered formulations include:
- HPMC capsules containing a moisture-sensitive small molecule, trimagnesium dicitrate and microcrystalline cellulose.
- The same formulation with stearic acid as a lubricant.
- The same formulation with silica as a glidant or moisture-management excipient.
- Dry-granulated mixtures of the active ingredient and trimagnesium dicitrate.
- Products packaged with an additional desiccant in a high-barrier container.
The claims do not expressly require a particular particle size, polymorph, salt form, dissolution profile, release profile or therapeutic indication. Those omissions broaden the formulation concept but may create prior-art and enablement pressure if the specification does not support a broad range of active ingredients.
How strong is the patent estate?
Based on the supplied claims, the patent has moderate claim breadth but several concentration points that limit enforcement.
Strengths
The patent has several features that can be difficult to design around simultaneously:
- HPMC capsule requirement;
- high trimagnesium dicitrate loading;
- active ingredient concentration range;
- microcrystalline cellulose range;
- moisture-performance limitation;
- optional dry granulation and external-desiccant features.
A product using the same capsule technology and the same internal drying strategy could face a credible infringement position, particularly if formulation-development documents show that trimagnesium dicitrate was selected to prevent hydrolysis.
The claims also cover a formulation result, low equilibrium moisture, rather than only an ingredient list. That may capture formulations with different excipient identities if they still meet the numerical and performance limitations.
Weaknesses
The most material weaknesses are:
- The active ingredient is not identified.
- The claims require a relatively high 20% to 50% trimagnesium dicitrate concentration.
- HPMC is mandatory.
- The formulation must be non-effervescent.
- Moisture performance must be established at 25°C.
- Claim 9 creates a potentially narrow and technically disputed measurement limitation.
- The formulation concept may face prior art involving magnesium salts, desiccant excipients, HPMC capsules and moisture-sensitive drugs.
The exclusion of trimagnesium dicitrate as the active ingredient prevents the claims from covering a product in which that compound is itself the pharmaceutical active.
When does US Patent 10,603,280 lose exclusivity?
The patent issued on March 31, 2020. Its exact expiration date depends on the earliest effective nonprovisional filing date, any patent-term adjustment, terminal disclaimer and any applicable patent-term extension. Patent term generally runs 20 years from the relevant U.S. nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. § 154.
The issue date alone cannot establish the expiration date. Patent-term adjustment may extend the term, while a terminal disclaimer may shorten it. A patent-term extension under 35 U.S.C. § 156 would require a qualifying regulatory product and would not be determinable from the claims alone.
The patent also does not create FDA regulatory exclusivity. Patent exclusivity and FDA exclusivity are separate rights.
What is the Orange Book status of US Patent 10,603,280?
The claims supplied do not identify a specific active ingredient, dosage strength or approved product. On that basis, an Orange Book listing cannot be tied to a particular drug product.
Orange Book listing generally depends on whether the patent claims a drug substance, drug product, formulation or method of use associated with an approved new drug application. A generic formulation patent may be listed if it meets FDA listing requirements, but a patent directed to a broad platform applicable to multiple active ingredients is not automatically Orange Book-listed.
A listing, if any, would need to be evaluated against:
- the approved product;
- the active ingredient identified in the NDA;
- the dosage form;
- the patent’s claim category;
- FDA patent-submission rules;
- any delisting or certification history.
The claims themselves do not establish an Orange Book listing.
What Paragraph IV risks exist?
A generic applicant could challenge the patent through an ANDA Paragraph IV certification if the patent is listed against the relevant reference-listed drug.
Potential design-around positions include:
| Design-around |
Likely effect |
| Use gelatin instead of HPMC |
Avoids the express capsule-shell limitation |
| Use less than 20% trimagnesium dicitrate |
Avoids the required drying-agent range |
| Use another magnesium salt or desiccant |
Avoids the trimagnesium dicitrate limitation |
| Use less than 5% microcrystalline cellulose |
Avoids the cellulose limitation |
| Use a tablet or powder sachet |
Avoids the HPMC capsule limitation |
| Use a moisture result above the claimed threshold |
May avoid the performance limitation |
| Use wet granulation or separate granulation |
Potentially avoids claim 8 |
| Omit external desiccant packaging |
Avoids claim 7 but not claims 1 or 9 |
A Paragraph IV case would likely focus on anticipation and obviousness involving known moisture-sensitive drugs, magnesium-based drying agents, HPMC capsules and cellulose fillers. The patentee would likely rely on comparative moisture-stability data, hydrolysis results and unexpected performance at the claimed composition ranges.
What patent litigation and settlements affect the patent?
The claim text does not establish litigation, settlement or licensing activity. No litigation status, Paragraph IV notice, consent judgment or settlement agreement should be attributed to US Patent 10,603,280 without a case-specific docket or regulatory record.
The relevant litigation questions are:
- whether the patent was listed against an approved product;
- whether an ANDA applicant filed a Paragraph IV certification;
- whether the patentee sued within 45 days;
- whether a 30-month stay was triggered;
- whether the case ended in settlement, judgment or dismissal;
- whether a terminal disclaimer or claim construction ruling affected the patent.
A formulation patent can have substantial commercial value without being litigated if the accused product uses a different capsule shell or drying system.
How does this patent compare with competing formulation patents?
US Patent 10,603,280 is a platform formulation patent. It differs from four common patent categories:
| Patent category |
Typical protected subject |
Comparison |
| Drug-substance patent |
Active molecule, salt or polymorph |
This patent does not claim a specific active molecule |
| Drug-product patent |
Formulation, dosage form or release profile |
This patent is closest to this category |
| Method-of-use patent |
Treatment indication or dosing regimen |
The supplied claims contain no therapeutic-use limitation |
| Manufacturing patent |
Granulation, blending or encapsulation process |
Claim 8 has a limited manufacturing feature |
Its strongest competitive position is against products that reproduce the same moisture-control design. Its position is weaker against products that preserve stability through coating, low-moisture excipients, separate packaging, alternative desiccants or a different dosage form.
What manufacturing and geographic barriers apply?
The patent is a U.S. right. Its claims do not by themselves block manufacture, sale or importation in Europe, Canada, Japan, China or other jurisdictions.
International risk depends on corresponding family members and their:
- granted claims;
- national validity;
- expiration dates;
- prosecution amendments;
- opposition history;
- claim scope;
- local patent-term adjustments.
For U.S. infringement, making, using, offering for sale, selling or importing a product that meets the claims can create exposure under 35 U.S.C. § 271. Manufacturing outside the United States does not eliminate U.S. risk if the product is imported or sold in the United States.
Claim 8 may create a manufacturing barrier only where the accused process uses dry granulation of the active ingredient and trimagnesium dicitrate together. Claims 1 and 9 create product-based risk regardless of whether the product was manufactured by dry granulation.
What revenue exposure and generic-entry scenarios are most plausible?
Revenue exposure cannot be assigned to the patent without identifying the active ingredient and approved product. The claims are not product-specific, so the patent’s value is binary at the product level: it matters if a commercial product adopts the claimed formulation.
The principal entry scenarios are:
- Direct infringement risk: the generic copies the HPMC capsule, composition ranges and moisture profile.
- Composition design-around: the generic changes trimagnesium dicitrate, cellulose or active-ingredient loading.
- Dosage-form design-around: the generic uses a tablet, gelatin capsule or coated multiparticulate.
- Measurement dispute: the generic contests whether the product meets the equilibrium-moisture limitation.
- Process separation: the generic avoids dry granulation while potentially remaining exposed to the composition claims.
- Validity challenge: the generic argues that the formulation was obvious in view of known moisture-sensitive products and desiccant excipients.
Key Takeaways
- US Patent 10,603,280 claims a moisture-stabilized HPMC capsule, not a particular drug.
- The mandatory core is 20% to 40% moisture-sensitive active ingredient, 20% to 50% trimagnesium dicitrate and 5% to 30% microcrystalline cellulose.
- Claims 1 and 9 differ in both the moisture threshold and the object being measured.
- Claims 7 and 8 add packaging and dry-granulation limitations that may be easier to design around.
- The patent’s commercial relevance depends on the active ingredient and marketed product using the claimed architecture.
- The claims do not establish FDA Orange Book listing, Paragraph IV litigation, licensing or settlement activity.
- Exact patent expiration requires the effective filing date, patent-term adjustment and any terminal disclaimer or extension.
- The primary generic-entry strategies are changing the capsule shell, drying agent, excipient ranges, dosage form or manufacturing process.
FAQs
Does US Patent 10,603,280 cover all moisture-sensitive drugs in HPMC capsules?
No. The formulation must also contain the specified ranges of trimagnesium dicitrate and microcrystalline cellulose and meet the claimed moisture limitation.
Can a product avoid the patent by using magnesium citrate in a different form?
Potentially. The claims specifically require trimagnesium dicitrate. A chemically distinct magnesium citrate material may avoid literal infringement, although equivalence and claim construction would require product-specific analysis.
Does using a gelatin capsule avoid the patent?
It likely avoids the express HPMC capsule limitation. A gelatin-capsule product could still implicate other patents in the same formulation family or separate patent estates.
Is dry granulation required for infringement of the main claims?
No. Dry granulation appears only in claim 8. Claims 1 and 9 are composition claims and do not require the dry-granulation step.
Can this patent block a generic after the patent expires?
No. Patent infringement liability under this patent generally ends when the enforceable patent term ends, subject to any applicable statutory term adjustment or extension. Other patents, regulatory exclusivities or trade-secret rights may still affect entry.
References
- United States Patent No. 10,603,280, claims 1-11 (issued Mar. 31, 2020).
- United States Code, 35 U.S.C. § 154. Patent term.
- United States Code, 35 U.S.C. § 156. Extension of patent term for regulatory review.
- United States Code, 35 U.S.C. § 271. Infringement of patent.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
